Climb Bio, Inc.
CLYM
Positions held
Your positionsCLYM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $623.76M | Enterprise value | $441.95M | Trailing P/E | — | Forward P/E | -10.83 |
| PEG | — | Price / book | 2.60 | Beta | -0.03 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -27.1% | ROA | -18.5% | Debt / equity | 0.01 |
| Current ratio | 31.45 | Free cash flow | -$33.99M | Analyst recommendation | strong_buy | Mean target | $27.57 |
| 52w high | $18.33 | 52w low | $1.64 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$13.5M | -$13.7M | -$17.5M | -$12.9M | -$8.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.4M | -$15.2M | -$19.3M | -$14.9M | -$10.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$67.9M | -$30.4M | -$40.3M | -$45.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
2026-10-01 · Raymond James Updates Healthcare Top Picks for October
2026-09-23 · The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
2026-09-08 · Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating
2026-09-04 · Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says
2026-09-04 · B. Riley Adjusts Price Target on Climb Bio to $30 From $26, Maintains Buy Rating
2026-09-04 · Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
2026-09-03 · Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
2026-09-03 · Update: Climb Bio Shares Fall After Early Phase 1 Data for IgA Nephropathy Drug
2026-09-03 · Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
2026-09-03 · Wedbush Adjusts Price Target on Climb Bio to $25 From $20, Keeps Outperform Rating
2026-09-03 · Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
Price (daily)
Full chart · RSI · MACD · patterns